Sentences with phrase «on pharmaceutical marketing»

Also on Croakey, Consumers Health Forum of Australia CEO Adam Stankevicius suggested it was «reasonable and rational» for patients to ask doctors about their views on pharmaceutical marketing.

Not exact matches

The guidelines rejected the possibility of full access to the EU's single market for crucial U.K. sectors such as finance and pharmaceuticals, stating there can be no «cherry picking» through participation based on a sector - by - sector approach.

The biggest company in Canada by market cap on the TSX — an admittedly capricious metric — is now Valeant Pharmaceuticals, which surpassed the Royal Bank of Canada this week.

While the MPA technology workswith any tangible product, Sproxil is focusing its efforts on the international pharmaceutical market.

He's hired a crisis PR firm, and run into another pharmaceutical company that has decided to market a competing drug to Turing's pyrimethamine (known on the market as Daraprim) for $ 1 per dose.

Jim Chanos, a well - known short - seller and market bear on companies like Tesla (tsla) and Alibaba (baba), is piling on to Valeant Pharmaceuticals» (vrx) misfortunes.

Major pharmaceuticals firms also engage in research and development, but tend to focus more on manufacturing and marketing an existing portfolio of drugs than the typical biotech firm.

April 18 Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

2017 Mid-Year Updates: [Published Aug. 2017] A 26 page mini-report featuring the latest market analysis on the hemp, legal marijauna and pharmaceutical CBD markets.

The iShares ETF is the largest covering the sector, tracking a set of biotechnology and pharmaceutical stocks that trade on the Nasdaq stock market.

These early objections were swept aside, however, and emergency contraception products are now available worldwide, with a pharmaceutical company in the United States even providing «full - on, direct - to - consumer marketing».

With the development of smarter packaging, this specialist for secondary packaging in the pharma / pharmaceutical and healthcare industry meets the needs of increased digitalisation on the e-health market and the growing interest in interactive packaging solutions.

Best Label a privately - owned label manufacturer on the West Coast with facilities in Mexico and California, has purchased and installed the Epson SurePress L - 6034VW to expand its short - run label printing offerings for customers in several markets, including food, beverage, health, beauty, pharmaceutical, nutraceutical, sports, automotive, agricultural, and chemical manufacturing.

The other 8 submissions posted since 21 July were from eBay, Global Shippers» Forum, NSW Taxi Council, Recruitment and Consulting Services Association, Sigma Pharmaceuticals Ltd, The Industry Group, The Infrastructure Group and the United States Federal Trade Commission (focus on misuse of market power, price signaling, and merger notification and review procedures).

Key Features: • Focuses on health claim legislation for this commercially important food sector • Includes chapters on the current situation in all the major world markets including Europe, the USA, Japan, India and China • Covers food, feed and pharmaceutical applications of probiotics

For the pharmaceutical market, the Combination Carton includes a printed and folded insert into paperboard cartons, eliminating the need to add the leaflet separately on the packaging line.

In 2007, its first full year on sale, it captured 36 percent of the organic formula market, with sales of more than $ 10 million, according to Kalorama Information, a pharmaceutical - industry research firm.

We're a pharmaceutical company that makes prescription - grade dermatology solutions, not just a cosmetics company like those brands that produce most of the sunscreens on the market.

Our review of reviews confirms that evidence exists from high quality studies on marketing of health - related products, such as tobacco, alcohol, pharmaceuticals, BMS, and marketing of foods to children, that marketing is effective, and conversely for most of these products, that comprehensive and evidence based regulation works to constrain it.

Shimsky, a Hastings - on - Hudson Democrat who first introduced the plan on June 19, told the Review the legislation would be directed against a number of pharmaceutical companies that have used deceptive marketing of opioid painkillers, seeking punitive and compensatory damages for the costs already expended by Westchester County.

Although the pharmaceutical industry, like the rest of the business world, has suffered a slowdown, the market research company Frost and Sullivan still expects spending on drug discovery to expand from US$ 19.6 billion in 2002 to US$ 25.6 billion by 2006, an annual growth rate of about 6 %.

Recalls of Cox - 2 inhibitor drugs during the past year have raised questions about the credibility of the U.S. Food and Drug Administration's (FDA's) regulation of new drugs and suspicions that pharmaceutical companies have been overly eager to put fresh remedies on the market.

Gomes said there are several potential explanations for the provincial differences in high - dose opioid prescribing, including varying coverage among public drug plans, training among prescribers and differential marketing on the part of pharmaceutical companies.

So, I took a job as a research scientist in the analytical lab of a smaller chemistry - driven, discovery - based pharmaceutical company located in Vancouver, B.C. With fewer than 100 employees and no products on the market, it couldn't have been further from the formal corporate work environment I was accustomed to at a multinational company.

$ 73.9 BILLION Average amount spent yearly on «marketing and administration» by 10 major pharmaceutical firms from 1996 through 2005, according to a report from the University of Quebec at Montreal.

This is what is known as idiosyncratic toxicity and is a big headache for the pharmaceutical industry, as it tends to be detected in late development stages of the drug and even when it is already on the market, often causing the drug to be withdrawn.

Cannabinoid receptors are part of a large class of receptors known as G protein - coupled receptors (GPCR), which account for about 40 percent of all prescription pharmaceuticals on the market, and play key roles in many physiological functions.

Fry points to exenatide, a molecule found in the venom of a lizard, the gila monster, and the newest venom - derived pharmaceutical on the US market.

Unlike pharmaceutical company - produced drugs, homeopathic products don't have to prove that they are effective at treating anything in particular before going on the market.

This revolutionary method, on the market since 1983, was the subject of heated debate at a meeting sponsored by a pressure group, the Women and Pharmaceuticals Project, at a health conference in Madrid in 1989.

The combination of scientific advances and economic improvement has had a marked impact on the Brazilian pharmaceutical market, which has increased 10-fold in the past 20 years and now ranks fifth in the world, with annual sales of about $ 12 billion.

The Food and Drug Administration is monitoring about 30 critical pharmaceuticals manufactured either solely or primarily on Puerto Rico — including 14 that can not be substituted by anything else on the market, FDA Commissioner Scott Gottlieb told a congressional panel yesterday.

The human enzymes corresponding to these 2 enzymes, CYP2B6 and CYP3A4 are reported to be related to the metabolism of more than half of the pharmaceuticals on the market.»

These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

HSCI has decided that Novasculgen will be available on ex-USSR pharmaceutical markets, and primarily it will be the market of Ukraine.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

CBR, a worldwide leader in newborn stem cell banking and research, is a part of AMAG Pharmaceuticals, a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people's lives.

Notably, over 30 % of the pharmaceuticals on the market are targeted at GPCRs.

According to a report in 2012 by BMJ, a London based medical journal, for every dollar pharmaceutical companies spent on «basic research,» they put another $ 19 toward marketing and greasing doctor's palms.

We looked long and hard for the best supplements on the market and chose USANA Health Sciences because of their pharmaceutical - grade manufacturing practices, which is a higher standard than organic.

But what most people may not know, is that some of the most powerful pharmaceutical drugs on the market, are made from plant extracts or based on natural, nutritional compounds.

While most all pharmaceutical production of Nilevar has stopped, more underground labs could start to put this steroid back into the black market if it catches on with the labs that have recently started producing it again.

Anabolicenergy.me offers high - quality Anavar for sale from Blakan Pharmaceuticals at the best price on the market.

«As a marketing tool, the strength of the corporate logo is that it can have multiplying effect on traditionally luxury product as people are more familiar with a brand that almost everyone at some point has bought, whether it's affordable furniture, a courier company or a pharmaceutical giant.»

Simply put, CROs work with pharmaceutical and device companies to help them develop their drugs and medical devices and bring them to the market, as well as work with clients after their product has been approved on post-marketing approval studies, as well as commercialization.

Research on pharmaceuticals is funded by private firms with one goal in mind: bringing profitable drugs to market.

Bristol - Myers Squibb Company is a global biopharmaceutical Company, which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis.

STERIS Corporation is a provider of infection prevention and surgical products and services, focused mainly on the critical markets of healthcare, pharmaceutical and research.

There wasn't a purely right or wrong answer because this was a fairly straight forward transaction, but Pfizer had just walked away from a deal with Allergan (April» 16) giving the market pause on current pharmaceutical mergers.